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We reviewed the early development of various focal ischemia models in spontaneously hypertensive rats (SHR), and
summarized recent reports on this topic. Among 6 focal ischemia models established in divergent substrains of
SHR, distal middle cerebral artery occlusion is the most frequently used and relevant method of focal ischemia in
the light of penumbra concept. We performed an online PubMed search (2001–2010), and identified 118 original
articles with focal ischemia in SHR. Physiological parameters such as age, body weight, and even blood pressure
were often neglected in the literature: the information regarding the physiological parameters of SHR is critical, and
should be provided within the methodology section of all articles related to stroke models in SHR. Although the
quality of recent studies on neuroprotective strategy is improving, the mechanisms underlying the protection
should be more clearly recognized so as to facilitate the translation from animal studies to human stroke. To
overcome the genetic heterogeneity in substrains of SHR, new approaches, such as a huge repository of genetic
markers in rat strains and the congenic strategy, are currently in progress.
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Almost 50 years have passed since the spontaneously
hypertensive rats (SHR) were established [1]. In the
present review, we will focus on the early development of
focal ischemia models in SHR, and provide a critical sys-
tematic review on recent reports on SHR stroke models.
SHR are one of the most widely used genetic models
for hypertension. Hypertension is a major risk factor
for stroke and most other cardiovascular diseases, and
therefore SHR are relevant to stroke research. SHR were
initially obtained by selective inbreedings from the
Wistar-Kyoto rats (WKY) with the highest blood pres-
sure. The stroke prone SHR (SHRSP) were established
from the A substrain of the SHR, and the other 2 sub-
strains (B and C) are resistant to spontaneous stroke [2].
The B substrain corresponds to SHR/Izm (Izumo). SHR* Correspondence: hyao@hizen2.hosp.go.jp
1Laboratory for Neurochemistry, Center for Emotional and Behavioral
Disorders, National Hospital Organization Hizen Psychiatric Center, Mitsu 160,
Yoshinogari, Kanzaki, Saga, 842–0192, Japan
Full list of author information is available at the end of the article
© 2012 Yao and Nabika; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumwere sent to the National Institute of Health (NIH) at the
F13 generation in 1966.
The advantages of using SHR in contrast to normoten-
sive rats in stroke research are: (1) presence of comorbid-
ity (i.e., hypertension), (2) reproducible and adequate-sized
infarction after distal middle cerebral artery occlusion
(MCAO) alone, and (3) a similar therapeutic time window
and cerebral blood flow (CBF) threshold for infarction to
normotensive rats [3,4]. Shortcomings are: (1) SHR and
SHRSP are expensive, (2) high mortality in aged SHR and
SHRSP, and (3) resistance to therapy. Another confound-
ing problem with using SHR in stroke research is that
SHR and WKY from different sources are genetically het-
erogeneous [5-7]. Because WKY are rarely used for focal
ischemia models or their controls in recent years, we do
not mention detailed descriptions of genetic heterogeneity
of WKY.
Stroke proneness and stroke sensitivity
Focal ischemia models are usually based on MCAO and
mimic human acute brain infarction caused by occlusion
of major cerebral arteries. Small vessel disease is anothertral Ltd. This is an Open Access article distributed under the terms of the
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tive impairment. Spontaneous stroke in SHRSP, often
under salt loading, is a unique and relevant feature of
SHRSP. The most preponderant site for spontaneous
stroke in SHRSP was the cortical area supplied by the an-
terior and posterior cerebral arteries with recurrent
branching [8]. A systematic review summarized that ani-
mals sacrificed after developing stroke-like symptoms dis-
played arteriolar wall thickening, subcortical lesions,
enlarged perivascular spaces and cortical infarcts and
hemorrhages [9]. Hainsworth and Markus [10] concluded
that to model small vessel disease-like arteriopathy,
SHRSP appears closest to human small vessel disease,
particularly in aged animals. In salt-loaded SHRSP, the
number of days necessary to develop stroke has been used
as an index of stroke proneness [11,12]. In contrast, in-
farct volume after MCAO is an index of stroke sensitivity.























Figure 1 Focal ischemia models in divergent substrains of spontaneo
Health (NIH) at the F13 generation in 1966 (SHR/N), and then from NIH to
their original breeding stocks of SHR from NIH in 1976, and Janvier started
Center, which in turn received their original breeding stocks from Kyoto Un
SHRSP/Bbb [Heidelberg]) were separated at F35, 36 in 1975. CNRS, Centre N
NIH, National Institute of Health; MCAO, middle cerebral artery occlusion; d
YAG, yttrium-aluminium-garnet (laser).rat [13]. Subsequently, the importance of hypertension
was emphasized in focal ischemia models [14-16]. Both
SHR and SHRSP have increased stroke sensitivity to focal
ischemia (i.e., larger infarct size after MCAO) compared
with normotensive rats [17]. Increased stroke sensitivity is
likely attributable to not only spontaneous hypertension
but also additional genetic factors that will be discussed
later. Many neuroprotective strategies in stroke research
are based on the penumbra concept constructed using
focal ischemia models [18]. In this context, focal ischemia
models are relevant to the human clinical setting of ische-
mic stroke or brain infarction.
Focal ischemia models in SHR
Distal MCAO
Six focal ischemia models have been established in SHR
and SHRSP (Figure 1). SHRSP maintained at the University

















usly hypertensive rats (SHR). SHR were sent to National Institute of
Charles River, Taconic Farms, and Harlan. In France, Iffa-Credo received
breedings in 1978 with SHR derived from the Delalande Research
iversity in 1974. Two colonies of SHRSP (SHRSP/A3N [NIH] and
ational de la Recherche Scientifique; SHRSP or SP, stroke prone SHR:
, distal; p, proximal; CCAO, common carotid artery occlusion;
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quences of MCAO distal to striate branches were studied
for the first time in SHRSP [14]. Even in young SHRSP
without chronic hypertension, distal MCAO produced lar-
ger lesions than WKY or Sprague–Dawley rats. This ap-
proach of Coyle was later employed by Fujii et al. to
investigate the beneficial effects of chronic antihypertensive
treatment on infarct size after MCAO: systolic blood pres-
sure in SHRSP was reduced to the level of WKY with anti-
hypertensive treatment after 3 months of age for
3 months, which reduced infarct volume by approxi-
mately 40% compared with untreated SHRSP [20]. The
inbred colonies of SHRSP, maintained in the Depart-
ment of Medicine and Therapeutics at the University of
Glasgow (SHRSPGla or SHRSP/Gcrc) since 1991, were
derived from the colony of University of Michigan.Proximal MCAO
The approach of Tamura et al., which occludes middle
cerebral artery (MCA) proximal to the lenticulostriate
arteries, produces infarction of both the cortex and the
lateral part of striatum [13]. Duverger and MacKenzie
employed the modified method of Tamura et al., using
SHRSP (Centre National de la Recherche Scientifique
[CNRS], France), SHR (Charles River, Italy), and 3
normotensive strains (WKY, Sprague-Dawley, and
Fischer-344) [15]. In hypertensive rats, MCAO resulted
in a considerable volume of infarction (158.1 ± 4.4 [SEM]
mm3 in SHR and 172.4 ± 4.4 [SEM] mm3 in SHRSP),
and the variability was minimum (coefficient of variation
[C.V.] = 7-8%) compared with the 3 normotensive strains
(C.V. = 20-49%). In the normotensive control WKY, the
infarction was small (63.2 ± 10.9 [SEM] mm3).Tandem MCAO
Brint et al. summarized their experience in 3 strains of
rats (SHR/Charles River or Taconic Farms, Wistar, and
Fisher-344 rats) with focal ischemia produced by tandem
occlusion of the distal MCA and ipsilateral common ca-
rotid artery [16]. Of the 3 strains of rats, the SHR
showed the largest (157–259 mm3) and most reprodu-
cible (average C.V. = 19%) infarctions, and statistical
power analysis revealed that tandem occlusion of the
distal MCA and ipsilateral common carotid artery in the
SHR strain offered a practical model in terms of requis-
ite animals necessary to avoid a Type 2 error (false nega-
tive) for differences in infarct volume between control
and experimental groups. Although infarct volume
might be more reproducible in SHR with tandem carotid
artery occlusion, the amount of penumbra tissue may
also be reduced. Consequently, it may be more difficult
to demonstrate neuroprotective efficacy in these models
with tandem occlusion.Photothrombotic MCAO
In the context of thrombosis, the effects of thrombotic
stroke on compromised brain tissue may be different
from those due to cerebral ischemia induced by mechan-
ical occlusions of intracranial or extracranial brain arter-
ies [21]. Prado et al. first used SHR as a photothrombotic
distal MCAO model, avoiding common carotid artery in-
volvement [22]. SHR/Kyushu and later SHR/Izm were
employed for photothrombotic distal MCAO [23,24]. The
SHR/Kyushu were from the F20 and F21 generations
derived by Okamoto and Aoki [25]. A photothrombotic
distal MCAO model in SHR yields a highly reproducible
infarct volume (average C.V. = 21%) and does not entail
extensive surgery or opening of the dura, thereby avoiding
unacceptable local tissue trauma at the site of MCAO
[17]. This model encompasses appropriate physiological
monitoring, associated risk factors for stroke, and clinic-
ally relevant pathophysiology of thrombosis. Cai et al.
showed the infarct size was larger in male and female
SHR/Kyushu than in SHR/Izm (i.e., substrain differences)
[24]. Because blood pressure levels were the same be-
tween the two substrains, factors other than hypertension
probably account for different lesion size. The ultraviolet
laser–induced reperfusion method, indicated as YAG
reperfusion in Figure 1, was also achieved by Watson
et al., [26] which was applied to SHR/Kyushu [23] and
later to SHR/Izm [27].
Intraluminal suture occlusion
The intraluminal suture model, developed by Koizumi
et al. [28] and Longa et al. [29], is undoubtedly the most
frequently used focal ischemia model in rats and mice
[30]. To our knowledge, Kawamura et al. first adopted
SHR for intraluminal suture model followed by a num-
ber of experiments with this method [31]. Alkayed et al.
investigated gender-linked brain injury in experimental
stroke produced by intraluminal suture occlusion in
SHRSP maintained in Johns Hopkins University from a
stock obtained from the NIH [32]. Some of the major
advantages of the intraluminal suture model are that it is
easy to perform, minimally invasive, and most import-
antly does not require craniectomy. However, it appears
that SHR can be replaced with normotensive rats in
many experiments with the use of the intraluminal su-
ture occlusion method except for the studies on antihy-
pertensive agents.
Although reperfusion of ischemic brain tissue is critical
for restoring normal function, it can paradoxically result
in secondary damage or reperfusion injury. Several lines
of evidence suggest that post-ischemic oxidative stress
and inflammation contribute to brain injury [33]. As
reperfusion injury is the condition of ischemia aggravated
by the occurrence of reperfusion more so than in the
case where reperfusion does not occur (i.e., permanent
Figure 2 Schematic representation of the ischemic penumbra.
Glucose utilization (anaerobic glycolysis) transiently increases at a
CBF value below about 40% of normal, which corresponds to the
beginning of acidosis with lactate accumulation. At a CBF value
below about 20% of normal, a breakdown of energy state begins
with reduced adenosine triphosphate (ATP), resulting in the
condition of ischemic core. The penumbra is defined as an area in
which metabolism is impaired due to reduced CBF, but the cellular
polarization is still maintained without diffusion- weighted imaging
lesions on magnetic resonance imaging. Therefore, an acidosis/
diffusion- weighted imaging mismatch represents penumbra.
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sary to make a comparison with permanent occlusion.
From a critical point of view, the intraluminal suture
model is a top of the internal carotid artery occlusion
model rather than a MCAO model [34]. Consequently,
this model has a wide ischemic zone, and because the
mortality rate is high in the case of permanent occlusion,
the permanent occlusion group and the reperfusion group
that shared the same time lapse cannot be compared.
The intraluminal suture model in SHR had a high inci-
dence of parenchymal hematomas, and therefore is ap-
propriate for the evaluation of reperfusion-associated
hemorrhagic transformation [35]. Hemorrhagic trans-
formation is one of the ultimate forms of reperfusion in-
jury. SHR subjected to 3 h of transient suture MCAO
had significant vascular injury or hemorrhagic infarction
compared to normotensive rats [36]. Yamashita et al.
demonstrated that tPA administered just before the
reperfusion of 4.5 h suture MCAO induced dissociation
of the neurovascular unit (i.e., the detachment of astro-
cyte endfeet from the basement membrane), which was
prevented by a free radical scavenger, edaravone [37].
Blood clot embolism
Although fibrinolytic therapy with tissue plasminogen ac-
tivator (tPA) is effective in the treatment of acute stroke,
there is an elevated risk of brain hemorrhage [38,39].
Hypertension is one of the factors related to the increased
incidence of hemorrhagic complications after tPA treat-
ment [40]. A novel model of tPA-induced hemorrhage
was examined in an embolic focal ischemia model with
homologous blood clots in SHR [41]. Blood pressure was
considered to be a critical correlate, because tPA-induced
extensive hemorrhagic transformation was observed in
SHR but not in normotensive WKY. Since reduction of
blood pressure with hydralazine, administered in the
drinking water for 1 week before MCAO, significantly
reduced the incidence of hemorrhagic transformation,
elevated blood pressure during tPA-induced reperfusion
is considered to contribute to the pathogenesis of
hemorrhage [42]. Therefore, SHR are relevant as a model
of embolic stroke as they demonstrate hemorrhagic trans-
formation after tPA therapy.
In the SHR clot embolism model, one study showed a
reduction of secondary hemorrhage after thrombolysis
combined with normobaric and hyperbaric oxygen ther-
apy [43], while normobaric oxygen did not interfere with
the beneficial action of tPA in another study [44].
Penumbra and the SHR stroke models
Penumbra, analogous to the half-shaded zone around a
solar eclipse, is the zone of salvageable tissue around the
ischemic core (Figure 2). The classic concept of ischemic
penumbra is defined as the condition of an ischemicbrain with CBF between the upper threshold of electrical
silence and the lower threshold of energy and ion pump
failure [18,45]. Regions having CBF in the ischemic core
range (CBF 0% to 20% of control values) had a 96%
probability of undergoing infarction, and zones of higher
CBF (>40% of control) were largely spared from infarc-
tion [46]. One of the most sensitive biochemical markers
of cerebral ischemia is the inhibition of protein synthe-
sis, which occurs above the upper threshold of classical
penumbra. Under experimental conditions, the most re-
liable way to localize the ischemic core is the loss of ad-
enosine triphosphate (ATP), and the biochemical marker
of the core plus penumbra is tissue acidosis [47]. There-
fore, pH-weighted magnetic resonance imaging and
diffusion-weighted imaging mismatch can provide a
more comprehensive zone of penumbra [48]. In the
clinical routine, however, perfusion-weighted imaging/
diffusion-weighted imaging mismatch is used as a surro-
gate marker for the penumbra: the early diffusion-
weighted imaging lesion might define the ischemic core,
while the adjacent critically hypoperfused tissue might be
identified as penumbra with perfusion-weighted imaging
[49]. Even after early reperfusion with tPA, the sustained
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indicates that the infarct core is well represented by the
acute diffusion lesion [50]. The linear increase in brain
sodium after MCAO, which indicates ischemic core, was
demonstrated directly by sodium magnetic resonance
imaging, and therefore sodium magnetic resonance im-
aging could provide a better measure of tissue viability
compared to diffusion-weighted imaging [51].
It has not been clear, however, which of the focal ische-
mia models in SHR is most relevant to the penumbra
concept. Proximal MCAO produces two ischemic vascu-
lar territories of lenticulostriate arteries and cortical
branches of MCA, the former of which are end-arteries
and therefore treatment-resistant with little penumbra.
The intraluminal suture model is a type of internal ca-
rotid artery occlusion model rather than a pure MCAO
model [34]. In clinical settings, the arterial obstruction
site strongly predicts infarct growth and clinical outcome:
internal carotid artery occlusion carried a uniformly poor
prognosis with poor response to tPA therapy [52]. Al-
though the infarcts produced by distal MCAO in normo-
tensive rats are small with presumably limited size of
penumbra, distal MCAO alone in SHR results in substan-
tial size of infarction. However, genetic hypertension (i.e.,
SHR) and induced renovascular hypertension resulted in
a larger lesion and smaller penumbra compared with
normotensive WKY after intraluminal suture occlusion
[53]. In the case of combined carotid artery occlusions,
concurrent carotid occlusions may excessively suppress
the retrograde collateral flow to the penumbra. Taken to-
gether, according to the ischemic penumbra concept, the
distal MCAO model without carotid artery involvement
is the best choice for human stroke (i.e., one major cere-
bral artery occlusion with collateral perfusion) among
SHR stroke models (Figure 2).
In our experience with distal MCAO in SHR, the early
restoration of perfusion confers advantages on the ische-
mic brain at risk. The cortical region, rescued by early
reperfusion, was considered to be the penumbral zone
[54]. At 6 h after MCAO, lesion volume (not infarction),
determined with 2,3,5-triphenyltetrazolium chloride
(TTC), was the same among the groups of permanent,
1 h, and 2 h MCAO, whereas 2 h and permanent MCAO
produced larger infarction than 1 h MCAO by approxi-
mately 2-fold after 24 h to 48 h [27]. Although TTC
methods underestimate the infarct volume because of re-
active gliosis, macrophage infiltration, and other prolifera-
tive responses in the infarction at later time points [55],
TTC staining is a convenient procedure and reliable for
detection of brain infarction at 24 h after the onset of is-
chemia [56]. Hence, the volume of penumbra is consid-
ered to be approximately 50% of final infarct volume in
our model. In the ischemic core, Na+ increased and K+
decreased progressively 3 h to 6 h after onset of ischemia,while these electrolytes were within normal values in the
acute phase of brain ischemia in the penumbral zone
[57]. In this stroke model, apoptotic internucleosomal
cleavage (DNA ladder), which is energy dependent, was
observed in the penumbral zone but not in the ischemic
core at 6 h after MCAO, which was preceded by large
DNA fragmentation in both penumbra and core at 3 h
after MCAO [58]. Protein synthesis is inhibited at a CBF
value clearly above the disturbance of glucose utilization
and energy metabolism. Attenuation or recovery of
deranged proteomic profile was slow even after a short
period of ischemia (i.e., 1 h MCAO). Nevertheless, it was
not permanently disturbed in the reperfused-penumbra,
while a derangement in proteomic profile appeared to be
an irreversible process in the ischemic core [59]. These
results also support the view that the distal MCAO model
in SHR provides a rational approach to the penumbra
concept.
MCAO experiments in SHR: A systematic review
We performed an online PubMed search based on the
terms “spontaneously hypertensive rats AND focal ische-
mia” with limits “English, and Animal” and analyzed all
original articles published between 2001 and 2010. We
also hand-searched 2 journals (Stroke and Journal of
Cerebral Blood Flow and Metabolism) that had pub-
lished a large proportion of relevant material. We identi-
fied 118 original articles dealing with focal ischemia in
SHR and SHRSP (Table 1). Stroke resistant or regular
SHR were used in 109 of 118 experiments (92%). Re-
cently, SHR have mostly been obtained from commercial
suppliers such as Charles River (SHR/NCrl), Taconic
Farms (SHR/NTac), Harlan (SHR/NHsd), Janvier, and
the Disease Model Cooperative Research Association or
Japan SLC (SHR/Izm) (80 of 118 experiments [68%]),
and SHR 19 (16%) were from research institutes.
Models of distal MCAO, distal MCAO combined with
ipsilateral common carotid artery occlusion, and photo-
thrombotic distal MCAO were all based on the occlu-
sion of distal portion of MCA: distal MCAO is the
predominant method (55 of 118 experiments [47%]) of
focal ischemia in SHR. The intraluminal suture model
was also frequently used (42 of 118 experiments [36%])
as expected.
In SHRSP/Izm, blood pressure was higher, and infarct
volume after MCAO was larger than SHR/Izm [27].
However, we found the survival rate after MCAO was
lower in SHRSP/Izm than SHR/Izm (87% vs. 99%) in
our recent experience. In most experiments with focal
ischemia, regular SHR are enough for the preclinical
testing of stroke therapies and elucidating the patho-
physiology of cerebral ischemia. Consequently, SHRSP
were not frequently used for focal ischemia models (9 of
118 [8%]).
Table 1 Focal ischemia models in spontaneously hypertensive
Author Substrains Age BW (g) MABP (mmHg) Methods of MCAO CBF References
Oyama N, et al. SHR/Charles River Jpan 10 wk NA 124±5 (SEM) intraluminal suture LDF J Neurosci Res 2010;88:2889-2898
Zhao X, et al. SHR/Harlan NA NA NA dMCAO+ipsi-CCAO (Brint) LDF Stroke 2010;41:363-367
Kranz A, et al. SHR/Charles River NA 250 NA pMCAO (Tamura) Brain Res 2010;1315:128-136
Yang Y, et al. SHR* NA 300-320 NA intraluminal suture J Neurochem 2010;112:134-149
Ito H, et al. SHR/Hos, Japan SLC 20-24 wk 346±33 209±13 photothrombotic dMCAO LDF J Cereb Blood Flow Metab 2010;30:343-351
Sun L, et al. SHR/Janvier France NA 300-350 120±11 blood clots embolism J Cereb Blood Flow Metab 2010;30:1651-1660
Porritt MJ, et al. SHR/ARC Australia 16 mo 438±11 SBP=200-210 intraluminal suture J Cereb Blood Flow Metab 2010;30:1520-1526
Yao H, et al. SHR/Izm, Japan SLC 5-7 mo 352±12 172±12 photothrombotic dMCAO/Re LDF Neurochem Res 2009;34:1999-2007
Yao H, et al. SHR/Izm, Japan SLC 5-7 mo NA 182 (mean) photothrombotic dMCAO/Re LDF J Cereb Blood Flow Metab 2009;29:565-574
McCabe C, et al. SHRSP/Gla 12-16 wk 220-390 93±4 intraluminal suture MRI Stroke 2009;40:3864-3868
Yan Y-P, et al. SHR/Charles River USA NA 270-320 NA intraluminal suture LDF Neurochem Int 2009;55:826-832
Ashioti M, et al. SHR/Charles River UK NA 200-250 NA dMCAO+ipsi-CCAO BMC Neurosci 2009;10:82
Ishikawa E, et al. SHR/Kyushu 5-8 mo 360-440 154±11 photothrombotic dMCAO LDF J Neurol Sci 2009;285:78-84
Omura-Matsuoka E, et al. SHR/Charles River Jpan 10-15 wk 250-350 181±10 intraluminal suture LDF Hypertens Res 2009;32:548-553
Cao F, et al. SHRSP* 13-15 wk 250-300 NA dMCAO Brain Res 2009;1272:52-61
Liu Y-P, et al. SHR/Charles River USA NA 290-310 130-140 intraluminal suture LDF J Cereb Blood Flow Metab 2009;29:780-791
Sasaki T, et al. SHR/Charles River Jpan NA 320±40 NA dMCAO+ipsi-CCAO (Brint) LDF Neurosci Lett 2009;449:61-65
Henning EC, et al. SHR/Charles River USA 3-4 mo 350±20 NA intraluminal suture J Cereb Blood Flow Metab 2009;29:1229-1239
Dharap A, et al. SHR/Charles River USA NA 280-300 NA intraluminal suture J Cereb Blood Flow Metab 2009;29:675-687
Ishibashi S, et al. SHR/Charles River USA 8 wk 180-220 NA dMCAO J Cereb Blood Flow Metab 2009;29:606-620
Yamashita T, et al. SHR/Izm, Japan SLC 13 wk 250-280 117±29 intraluminal suture LDF J Cereb Blood Flow Metab 2009;29:715-725
Fujiwara N, et al. SHR/Charles River USA NA 303±8 183±6 blood clots embolism LDF BMC Neurosci 2009;10:79
Murata Y, et al. SHR/Charles River USA NA 283±8 184±5 blood clots embolism LDF Stroke 2008;39:3372-3377
Matsuzaki T, et al. SHR/Izm, Japan SLC 9 wk 240-290 126±17 intraluminal suture LDF Neurol Res 2008;30:531-535
Kozak W, et al. SHR/Charles River USA 12-13 wk 275-300 135±8 (telemetry) intraluminal suture LDF J Pharmacol Exp Ther 2008;326:773-782
Henning EC, et al. SHR/Charles River USA 3-4 mo 300-360 SBP=165-185 intraluminal suture Stroke 2008;39:3405-3410
Park S-W, et al. SHR/Charles River USA NA 250-350 NA intraluminal suture LDF J Neurosurg 2007;107:593-599
Korde AS, et al. SHR/Harlan NA 250-350 94±3 dMCAO+ipsi-CCAO (Brint) LDF J Neurotrauma 2007;24:895-908
Kurasako T, et al. SHR/Harlan NA 220-300 101±12 dMCAO+ipsi-CCAO (Brint) J Cereb Blood Flow Metab 2007;27:1919-1930
Jimenez-Altayo F, et al. SHR/Janvier Spain 13-15 wk 341±4 (SEM) SBP=204±2 (SEM) intraluminal suture Am J Physiol Heart Circ Physiol 2007;293:H628-635
Tureyen K, et al. SHR/Charles River USA NA NA 135±9 intraluminal suture LDF J Neurochem 2007;101:41-56
Yao H, et al. SHRSP/Izm, Japan SLC 5 mo 315±30 241±22 photothrombotic dMCAO LDF Physiol Genomics 2007;30:69-73



















Table 1 Focal ischemia models in spontaneously hypertensive (Continued)
Mariucci G, et al. SHR/Charles River Italy 12-14 wk 250-330 NA pMCAO (Tamura) Neurosci Lett 2007;415:77-80
Adibhatla RM, et al. SHR/Charles River USA NA 250-300 NA intraluminal suture Brain Res 2007;1134:199-205
Leker RR, et al. SHR/Tel Aviv NA NA NA dMCAO Stroke 2007;38:153-161
Kumai Y, et al. SHR/Kyushu 5-8 mo 340-435 164±2 (SEM) photothrombotic dMCAO LDF J Cereb Blood Flow Metab 2007;27:1152-1160
Yang Y, et al. SHR* NA 300-320 NA intraluminal suture J Cereb Blood Flow Metab 2007;27:697-709
Yan Y-P, et al. SHR/Charles River USA NA 270-300 NA intraluminal suture LDF J Cereb Blood Flow Metab 2007;27:1213-1224
Takasawa M, et al. SHR/Charles River UK NA 295-305 NA dMCAO+ipsi-CCAO J Cereb Blood Flow Metab 2007;27:679-689
Akaiwa K, et al. SHR* NA 250-290 144±5 intraluminal suture LDF Brain Res 2006;1122:47-55
Yan Y-P, et al. SHR/Charles River USA NA 250-300 130-140 intraluminal suture LDF Eur J Neurosci 2006;24:45-54
Lammer A, et al. SHR/Charles River Germany NA 250-300 NA pMCAO (Tamura) Eur J Neurosci 2006;23:2824-2828
Bowen KK, et al. SHR/Charles River USA NA 280-320 NA intraluminal suture LDF Neurochem Int 2006;49:127-135
Komitova M, et al. SHR/Mollegaard 6 mo NA NA dMCAO Exp Neurol 2006;199:113-121
Zhao L, et al. SHR/Charles River USA NA 250-350 118±12 dMCAO+ipsi-CCAO (Brint) AR / LDF J Cereb Blood Flow Metab 2006;26:1128-1140
Zhang B, et al. SHRSP* 16-18 wk NA 204±7 dMCAO J Cereb Blood Flow Metab 2006;26:708-721
Furuya K, et al. SHR/Charles River Jpan NA 280-320 NA dMCAO+ipsi-CCAO (Brint) LDF J Neurosurg 2005;103:715-723
Kamiya T, et al. SHR/Harlan NA 225-325 161±13 dMCAO+ipsi-CCAO (Brint) AR Stroke 2005;36:2463-2467
Naylor M, et al. SHR/Charles River USA NA 280-320 NA intraluminal suture LDF Neurochem Int 2005;47:565-572
Adibhatla RM, et al. SHR* NA 250-275 NA intraluminal suture LDF Brain Res 2005;1058:193-197
Tsuji K, et al. SHR* NA 260-280 NA intraluminal suture LDF Stroke 2005;36:1954-1959
Gunther A, et al. SHR/Charles River Germany NA 250-330 NA pMCAO (Tamura) Eur J Neurosci 2005;21:3189-3194
Vemuganti R SHR/Charles River USA NA 280-320 NA intraluminal suture LDF Neurochem Int 2005;47:136-142
Komitova M, et al. SHR/Mollegaard 6 mo 300-370 NA dMCAO Eur J Neurosci 2005;21:2397-2405
Onoue S, et al. SHRSP* NA 280-320 NA dMCAO+ipsi-CCAO (Brint) Brain Res Mol Brain Res 2005;134:189-197
Hobohm C, et al. SHR/Charles River Germany NA 250-330 NA pMCAO (Tamura) J Neurosci Res 2005;80:539-548
Drummond JC, et al. SHR/Harlan 16-20 wk 375-425 131±9 intraluminal suture Anesth Analg 2005;100:841-846
Ooboshi H, et al. SHR/Kyushu 5-8 mo 340-430 NA photothrombotic dMCAO LDF Circulation 2005;111:913-919
Takada J, et al. SHR/Kyushu 7-8 mo 352-450 153±10 photothrombotic dMCAO LDF Gene Ther 2005;12:487-493
Kumai Y, et al. SHR/Kyushu 5-10 mo 320-400 181±21 photothrombotic dMCAO LDF J Cereb Blood Flow Metab 2004;24:1359-1368
Carswell HV, et al. SHRSP/Gla, female 3-4 mo 179±11 140±15 dMCAO J Cereb Blood Flow Metab 2004;24:298-304
Franke H, et al. SHR/Charles River Germany NA 250-330 NA pMCAO (Tamura) J Neuropathol Exp Neurol 2004;63:686-699
Zhang B, et al. SHRSP* 12-13 wk 250-300 NA dMCAO Neuroscience 2004;126:433-440
Dhodda VK, et al. SHR/Charles River USA NA 280-320 NA intraluminal suture LDF J Neurochem 2004;89:73-89
Nurmi A, et al. SHR/M&B A/S NA NA NA pMCAO Stroke 2004;35:987-991



















Table 1 Focal ischemia models in spontaneously hypertensive (Continued)
Ren Y, et al. SHR/Harlan NA 250-300 124±16 dMCAO+ipsi-CCAO (Brint) J Cereb Blood Flow Metab 2004;24:42-53
Kumai Y, et al. SHR/Kyushu, female 5-7 mo 195-240 170±2 (SEM) photothrombotic dMCAO LDF Exp Neurol 2003;184:904-911
Babu GN, et al. SHR* NA 250-300 NA intraluminal suture LDF Neurochem Res 2003;28:1851-1857
Gautier S, et al. SHR/Elevage Janvier France NA 270-320 NA intraluminal suture Stroke 2003;34:2975-2979
Asahi M, et al. SHR/Taconic Farms NA NA NA blood clots embolism LDF J Cereb Blood Flow Metab 2003;23:895–899.
Teichner A, et al. SHR* 13 wk NA NA dMCAO Exp Neurol 2003;182:353-360
Sadanaga-Akiyoshi F, et al. SHR/Kyushu 5-7 mo 315-425 178±11/176±7 photothrombotic dMCAO LDF Neurochem Res 2003;28:1227-1234
Dahlqvist P, et al. SHR/Mollegaard 14-15 wk NA NA dMCAO Neuroscience 2003;119:643-652
Pettigrew LC, et al. SHR/Harlan NA 250-300 98±17 dMCAO+ipsi-CCAO (Brint) Neurol Res 2003;25:201-207
Yan Y, et al. SHR/Charles River USA NA 270-310 133±9 intraluminal suture Brain Res 2003;961:22-31
Yamakawa H, et al. SHR/Taconic Farms 12 wk 300-500 SBP=156±4 dMCAO J Cereb Blood Flow Metab 2003;23:371-380
Wiessner C, et al. SHR/Iffa Credo NA 220-300 NA dMCAO J Cereb Blood Flow Metab 2003;23:154-165
Rao VLR, et al. SHR/Charles River USA NA 280-320 NA intraluminal suture LDF J Neurochem 2002;83:1072-1086
Aoki T, et al. SHR* NA NA 177±6 blood clots embolism LDF Stroke 2002;33:2711-2717
Leker RR, et al. SHR/Tel Aviv 13 wk NA 127±11 dMCAO LDF Exp Neurol 2002;176:355-363
Leker RR, et al. SHR/Tel Aviv 13 wk NA 127±5 dMCAO LDF Stroke 2002;33:1085-1092
Adibhatla RM, et al. SHR* NA NA NA intraluminal suture Brain Res 2002;938:81-86
Sakakibara Y, et al. SHR/Charles River USA NA 280-350 116-128 intraluminal suture Brain Res 2002;931:68-73
Sumii T, et al. SHR/Taconic Farms NA NA 185±6 (SEM) blood clots embolism LDF Stroke 2002;33:831-836
Jin J, et al. SHR/Hos, Japan SLC NA 130-160 NA pMCAO AR Pharmacology 2002;64:119-125
Higuchi T, et al. SHR/Charles River Jpan NA 261±32 88±12 dMCAO+ipsi-CCAO (Brint) LDF J Cereb Blood Flow Metab 2002;22:71-79
Ito T, et al. SHR/Taconic Farms 8 wk 190-240 SBP=153±6 (SEM) dMCAO Stroke 2002;33:2297-2303
Wallace JA, et al. SHR* NA 280-320 NA intraluminal suture J Cereb Blood Flow Metab 2002;22:1303-1310
Komitova M, et al. SHR/Mollegaard NA NA NA dMCAO J Cereb Blood Flow Metab 2002;22:852-860
Johanson BB, et al. SHR/Mollegaard 3 mo NA NA dMCAO J Cereb Blood Flow Metab 2002;22:89-96
Dijkhuizen RM, et al. SHR/Taconic Farms NA 300-350 NA blood clots embolism MRI Stroke 2002;33:2100-2104
Yao H, et al. SHR/Kyushu 5-7 mo 346-444 196 (mean) photothrombotic dMCAO/Re LDF Neuroreport 2002;13:1005-1008
Kitayama J, et al. SHR/Kyushu 5-8 mo 305-438 161±5 (SEM) photothrombotic dMCAO LDF Brain Res 2001;922:223-228
Furuya K, et al. SHR* NA NA NA dMCAO+ipsi-CCAO (Brint) Stroke 2001;32:2665-2674
Takagi K, et al. SHR/Funabashi Farm Japan 15-16 wk 280-340 177±11 pMCAO (Tamura) LDF Neurol Res 2001;23:662-668
Cole DJ, et al. SHR* 16-20 wk 375-425 126±9 / 131±7 intraluminal suture Can J Anaesth 2001;48:807-814
Yan Y, et al. SHR/Charles River USA NA 270-300 133±8 intraluminal suture J Cereb Blood Flow Metab 2001;21:711-721
Rao VLR, et al. SHR/Charles River USA NA 250-300 116±11 intraluminal suture LDF J Cereb Blood Flow Metab 2001;21:945-954



















Table 1 Focal ischemia models in spontaneously hypertensive (Continued)
Marks L, et al. SHRSP/Gla 3-5 mo 262±11 (SEM) 123±9 (SEM) dMCAO Hypertension 2001;38:116-122
Gregersen R, et al. SHR/Mollegaard NA 300-335 NA pMCAO Exp Brain Res 2001;138:384-392
Yao H, et al. SHR/Kyushu 5-7 mo 350-438 187 (mean) photothrombotic dMCAO LDF Brain Res Mol Brain Res 2001;91:112-118
Tejima E, et al. SHR* NA 250-300 122±3 (SEM) blood clots embolism LDF Stroke 2001;32:1336-1340
Lavie G, et al. SHR/Tel Aviv 13 wk NA 127±11 dMCAO Brain Res 2001;901:195-201
Furuya K, et al. SHR/Charles River USA 13-16 wk NA 140±7 pMCAO (Tamura) J Cereb Blood Flow Metab 2001;21:226-232
Holtz ML, et al. SHR/Harlan NA 250-350 108±15 dMCAO+ipsi-CCAO (Brint) Brain Res 2001;898:49-60
Fredduzzi S, et al. SHR/Charles River Italy 12-14 wk 250-330 NA pMCAO (Tamura) Neurosci Lett 2001;302:121-124
Rao VLR, et al. SHR/Charles River USA NA 250-300 NA intraluminal suture LDF J Neurosci 2001;21:1876-1883
Negrin CD, et al. SHRSP/Gla 13 wk NA SBP=186±6 (SEM) dMCAO Hypertension 2001;37:391-397
Babu GN, et al. SHR* NA 250-300 NA intraluminal suture LDF Neurosci Lett 2001;300:17-20
Legos JJ, et al. SHR/Taconic Farms NA 300-350 NA dMCAO Brain Res 2001;892:70-77
Slivka AP, et al. SHR* NA 240-400 NA dMCAO+ipsi-CCAO (Brint) Exp Neurol 2001;167:166-172
Barone FC, et al. SHR/Taconic Farms NA 290-340 141±3 (SEM) dMCAO J Pharmacol Exp Ther 2001;296:312-321
Relton JK, et al. SHR/Taconic Farms NA 250-350 168±15 (SEM) intraluminal suture Stroke 2001;32:199-205
Ooboshi H, et al. SHR/Kyushu 5-7 mo 340-430 167±6 (SEM) photothrombotic dMCAO LDF Stroke 2001;32:1043-1047
Dijkhuizen RM, et al. SHR/Taconic Farms NA 300-350 NA blood clots embolism LDF / MRI J Cereb Blood Flow Metab 2001;21:964-971
*substrain unknown; NA, not available. Values are mean ± S.D. BW, body weight; MABP, mean arterial blood pressure;
MCAO, middle cerebral artery occlusion; d, distal; p, proximal; ipsi, ispsilateral; Re, reperfusion;



















Yao and Nabika Journal of Translational Medicine 2012, 10:139 Page 10 of 17
http://www.translational-medicine.com/content/10/1/139Resting blood pressure values were available in 62
(53%) articles, while we could not find a description of
blood pressure in 56 (47%) articles. The information on
blood pressure of SHR is apparently lacking in a substan-
tial amount of literature. Of 35 experiments with stand-
ard inhalation anesthesia, rats were intubated, and the
anesthesia was maintained with low concentrations of
halothane or isoflurane in 13 experiments, while high
concentrations of anesthesia were used in 22 experiments
often with a facemask in the spontaneously breathing
animal. Resting MABP levels were significantly lower
(median 132, interquartile range [IQR] 122–140) in those
with high concentrations of anesthesia than those (me-
dian 177, IQR 164–182) with low concentrations of
anesthesia (Mann–Whitney u-test, p = 0.000) (Figure 3).
There is general agreement that hypotension during
acute stroke is detrimental to perfusion of ischemic brain
and tissue outcome [60]. CBF autoregulation was lost
when CBF fell below 30% of normal tissue [61]. Arterial
blood pressure had a greater influence on CBF in moder-
ately ischemic brain tissue, suggesting potential benefits
from raising and possible harm from lowering intrais-
chemic blood pressure. Zhu and Auer (1995) studied the
effects of halothane-induced hypotension on histological
outcome after transient intraluminal suture occlusion in
Wistar rats [62]. Intraischemic hypotension significantly
increased infarct size, and the penumbra, defined here as
the zone with selective neuronal necrosis, was lost at a
blood pressure of 40 mmHg. In line with these observa-
tions, mechanical ventilation was required to obtain con-
trolled experimental conditions in focal brain ischemia:

























Figure 3 Box and whisker plot of resting mean arterial blood pressur
The box shows median value and 25th and 75th percentiles. *P=0.000 for d
(Mann–Whitney u-test).chloral hydrate i.p. or with halothane via facemask,
exhibited respiratory acidosis and decreased blood pres-
sure, resulting in high mortality and a significantly
increased infarct volume [63].
In SHR, blood pressure levels are classified into 3 time
points as follows: (1) the prehypertensive period (4 weeks),
(2) the period of rapidly rising blood pressure (8 and
12 weeks), and (3) sustained hypertension (16–18 weeks)
[64]. Blood pressure of SHR rises between 1 and 5 months,
and blood pressure as well as body weight remain con-
stant thereafter [65]. Survival rate of male SHR/Kyushu
declines sharply after 15 months of age. Infarct volume in
the young SHRSP (10–12 weeks) was substantially smal-
ler than that in adult SHRSP (5 months) [66]. On the
basis of these observations, SHR should be used at 5 to
7 months and SHRSP at 5 months for adult models of
focal ischemia. Age as well as body weight should be
described in the manuscript to better understand the
effects of age on ischemic insults in SHR. We analyzed a
possible chronological variability of physiological variables
in adult male SHR/Izm (5–7 months old, n = 195) used
between 2005 and 2010 for our stroke research, and found
that resting MABP in 2009–2010 (163± 9 [S.D.] mmHg)
was significantly lower than those in 2005–2006 and
2007–2008 (175± 10 mmHg and 173± 9 mmHg, respect-
ively) (ANOVA and Scheffe test, p = 0.000), while the
mean values of body weight were fairly constant (unpub-
lished observation). This observation suggests that MABP
could fluctuate even in the closed colony of SHR/Izm
under strict monitoring of blood pressure. Physiological
parameters of SHR – notably blood pressure, arterial
gases, and brain as well as systemic temperature - shouldHigh
e in experiments with low and high concentrations of anesthesia.
ifference in mean arterial blood pressure between the groups
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http://www.translational-medicine.com/content/10/1/139be closely monitored and regulated in each experiment.
The monitoring of brain temperature, reflected by tem-
poralis muscle (or skull) temperature, would be recom-
mended even in closed skull models such as the
intraluminal thread model, because studies that used only
rectal temperature measurements may be confounded by
unknown variations in brain temperature [67].
Sex differences influence both stroke mechanism and
response to therapy [24,68,69]. However, female SHR
were only rarely used (2 of 118) (Table 1).
Among the 118 experiments mentioned above, 58
studies tested the efficacy of neuroprotective strategy
(Table 2). We assessed the quality of these studies
according to published criteria by Macleod et al. [70]
with slight modification. These criteria were: (1) peer-
reviewed publication, (2) compliance with animal welfare
regulations, (3) use of anesthetic without significant in-
trinsic neuroprotective activity, (4) statement of control
of physiological variables, (5) statement of control of
brain/head temperature, (6) random allocation to treat-
ment or control, (7) blinded induction of ischemia, (8)
blinded assessment of outcome, (9) sample size calcula-
tion, and (10) statement of potential conflict of interests.
Since statements on conflict of interest have only re-
cently appeared in the pre-clinical stroke literature
(2008–2010), this item was not included in the total
score, and each study was given a quality score out of a
possible total of 9 points. The median quality score was
5.0 (IQR of 4.0-6.0), which was apparently higher than
the 3.5 reported by Macleod et al. [70] (experiments
published between 1998 and 2003) even considering the
minor differences in criteria between the studies, sug-
gesting improved quality of experiments in recent years
after the Stroke Therapy Academic Industry Roundtable
(STAIR) recommendations [71] and a series of meta-
analyses of studies of experimental stroke [70,72,73].
The STAIR-defined criteria for the development and
improved clinical testing of neuroprotective drugs are:
adequate dose–response data, definition of the time win-
dow, blinded and physiologically controlled reproducible
studies, hisotological and functional outcomes assessed
acutely and long-term, and testing in both permanent
and transient MCAO models. High socres (≧6) were
largely due to 3 criteria: use of anesthetic without signifi-
cant intrinsic neuroprotective activity, statement of con-
trol of physiological variables, and statement of control of
brain/head temperature. A power or sample size calcula-
tion was given only in 4 of 58 studies. “Blinded” induction
of ischemia or assessment of outcome was described in
8 studies, 7 of which scored high points (≧6). After
complete randomization, blinded assessment should be
followed for good laboratory practice. Quality of studies
with lower scores (≦4) (21 of 58 [36%]) were considered
to be inadequate by today’s standards. In addition to thecriteria mentioned above, we propose that mortality rate
after MCAO surgery should be described.
Despite the progress in experimental stroke models,
however, the recent angiotensin-receptor blocker cande-
sartan for treatment of acute stroke trial (SCAST) failed
to show any beneficial effects in elderly patients with
acute stroke and raised blood pressure [74], whereas par-
tial lowering of the blood pressure during reperfusion
was beneficial in young SHR [75]. Age may be a factor
that accounted for the discrepancy between the pre-
clinical animal experiments and the clinical trial in aged
patients. Furthermore, besides the inevitable differences
between the animal experiments and human stroke, the
most critical point of the disparity in the SCAST sce-
nario was that the animal model mimicked the situation
of large vessel occlusion, while a substantial portion of
the patients in the SCAST study had the cerebral small
vessel disease: 29% had lacunar syndrome and 14%
hemorrhagic stroke. It is unlikely that a neuroprotective
drug acts on lacunar stroke or brain hemorrhage the
same as it does on embolic stroke. The mechanistic
aspects of the therapeutic strategy should not be left out
of accounts of either animal or human studies, since dif-
ferent mechanisms of protection between experimental
and clinical settings may lead to failure in translational
research.
Cerebral blood flow
Among the 118 articles (2001–2010) on Table 1, CBF
was determined in 60 experiments: 56 with laser-
Doppler flowmetry, 3 with autoradiography, and 3 with
magnetic resonance imaging. One study with autoradi-
ography also adopted 2-dimensional laser-Doppler per-
fusion imaging (Moor Instruments, Inc.), and in another
study both magnetic resonance imaging and laser-
Doppler flowmetry were used. One of the major advan-
tages of the magnetic resonance imaging method was
that this noninvasive modality provided additional infor-
mation such as diffusion-weighed imaging [76,77] and
hemorrhagic transformation [77] in addition to perfu-
sion imaging. The power of CBF autoradiography lies in
its ability to quantitate the local CBF in small discrete
brain regions, although flow can be assessed only once
and sacrifice of the animal is required. With regard to
focal ischemia models, the golden standard of CBF
measurement is the quantitative 3-dimensional autoradi-
ography [46]. Laser-Doppler flowmetry is an easy
method to monitor a relative measure of blood perfu-
sion, and is commonly used in small animals. Practical
considerations in this method include confounding
effects such as superfluous light, heterogeneous distribu-
tion of superficial blood vessels, and movement artifacts.
In the studies of focal ischemia, one-point CBF measure-
ment with laser-Doppler flowmetry may show no
Table 2 Quality of neuroprotective studies




































2009 1 1 1 1 0 1 1 0 1 0 7
Drummond JC,
et al.
2005 1 1 1 1 1 1 0 1 0 0 7
Yan Y,
et al.
2001 1 1 1 1 1 1 0 1 0 0 7
Ito H,
et al.
2010 1 1 1 1 1 1 0 0 0 0 6
Ishikawa E,
et al.
2009 1 1 1 1 1 1 0 0 0 0 6
Yamashita T,
et al.
2009 1 1 1 1 1 1 0 0 0 0 6
Kumai Y,
et al.
2007 1 1 1 1 1 1 0 0 0 0 6
Zhang B,
et al.
2006 1 1 1 0 1 1 0 1 0 0 6
Kamiya T,
et al.
2005 1 1 1 1 1 1 0 0 0 0 6
Ooboshi H,
et al.
2005 1 1 1 1 1 1 0 0 0 0 6
Takada J,
et al.
2005 1 1 1 1 1 1 0 0 0 0 6
Kumai Y,
et al.
2004 1 1 1 1 1 1 0 0 0 0 6
Vemuganti R,
et al.
2004 1 1 1 1 1 1 0 0 0 0 6
Ren Y, et al. 2004 1 1 1 1 1 1 0 0 0 0 6
Sadanaga-
Akiyoshi F, et al.
2003 1 1 1 1 1 1 0 0 0 0 6
Yan Y, et al. 2003 1 1 1 1 1 1 0 0 0 0 6
Sakakibara Y,
et al.
2002 1 1 1 1 0 1 0 1 0 0 6
Kitayama J,
et al.
2001 1 1 1 1 1 1 0 0 0 0 6
Furuya K,
et al.
2001 1 0 1 1 1 1 0 1 0 0 6
Rao VLR,
et al.
2001 1 1 1 1 1 1 0 0 0 0 6
Furuya K,
et al.
2001 1 1 1 1 1 1 0 0 0 0 6
Rao VLR,
et al.
2001 1 1 1 1 1 1 0 0 0 0 6
Slivka AP,
et al.
2001 1 1 1 1 0 1 0 1 0 0 6
Oyama N,
et al.
2010 1 1 1 1 0 1 0 0 0 0 5
Sun L,
et al.
2010 1 1 1 1 0 1 0 0 0 1 5
Ashioti M,
et al.
2009 1 1 1 0 0 1 0 0 1 0 5
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Table 2 Quality of neuroprotective studies (Continued)
Liu Y-P,
et al.
2009 1 1 1 1 0 1 0 0 0 0 5
Murata Y,
et al.
2008 1 1 1 1 0 1 0 0 0 1 5
Matsuzaki T,
et al.
2008 1 1 1 1 0 1 0 0 0 0 5
Korde AS,
et al.
2007 1 1 0 1 1 1 0 0 0 0 5
Tureyen K,
et al.
2007 1 1 1 1 0 1 0 0 0 0 5
Adibhatla RM,
et al.
2005 1 1 1 1 0 1 0 0 0 0 5
Carswell HV,
et al.
2004 1 1 1 1 0 1 0 0 0 0 5
Asahi M,
et al.
2003 1 1 1 1 0 1 0 0 0 0 5
Pettigrew LC,
et al.
2003 1 1 0 1 1 1 0 0 0 0 5
Takagi K, et al. 2001 1 1 1 1 0 1 0 0 0 0 5
Zhao Z, et al. 2001 1 1 1 1 0 1 0 0 0 0 5
Zhao X, et al. 2010 1 1 0 1 0 1 0 0 0 1 4
Porritt MJ, et al. 2010 1 0 1 0 0 1 0 0 1 1 4
Omura-Matsuoka
E, et al.
2009 1 1 1 0 0 1 0 0 0 1 4
Kozak W, et al. 2008 1 1 1 0 0 1 0 0 0 0 4
Zhang B, et al. 2004 1 1 1 0 0 1 0 0 0 0 4
Nurmi A, et al. 2004 1 1 0 1 0 1 0 0 0 0 4
Wiessner C,
et al.
2003 1 1 1 0 0 1 0 0 0 0 4
Leker RR, et al. 2002 1 1 0 0 0 1 0 0 1 0 4
Jin J, et al. 2002 1 1 1 0 0 1 0 0 0 0 4
Lavie G, et al. 2001 1 1 0 0 0 1 0 1 0 0 4
Relton JK, et al. 2001 1 1 1 0 0 1 0 0 0 0 4
Lammer A,
et al.
2006 1 1 0 0 0 1 0 0 0 0 3
Gunther A,
et al.
2005 1 1 0 0 0 1 0 0 0 0 3
Teichner A,
et al.
2003 1 1 0 0 0 1 0 0 0 0 3
Yamakawa H,
et al.
2003 1 1 0 0 0 1 0 0 0 0 3
Ito T, et al. 2002 1 1 0 0 0 1 0 0 0 0 3
Fredduzzi S,
et al.
2001 1 1 0 0 0 1 0 0 0 0 3
Barone FC,
et al.
2001 1 1 0 0 0 1 0 0 0 0 3
Kranz A, et al. 2010 1 0 0 0 0 1 0 0 0 0 2
Leker RR, et al. 2002 1 0 0 0 0 1 0 0 0 0 2
Legos JJ, et al. 2001 1 0 0 0 0 1 0 0 0 0 2
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http://www.translational-medicine.com/content/10/1/139significant (a false negative) difference in CBF after
MCAO between the groups. To overcome this issue, we
determined CBF with the laser-Doppler flowmetry
“scanning” method as previously described [66]: a laser-
Doppler flowmetry probe was laterally scanned, and CBF
of the distal MCA territory was measured at five points
(2 mm posterior and 2.0, 2.5, 3.0, 3.5, and 4.0 mm lateral
to the bregma), and 5 CBF values in one rat were trans-
formed to an area under curve according to the trapez-
oidal rule. This “scanning” method worked well, but it is
time-consuming and requires much effort. Two-
dimensional cortical CBF mapping is possible with laser-
Doppler perfusion imaging, which is a sophisticated and
robust image registration [78,79]. This system, however,
requires an expensive set-up.
Beyond substrains
To overcome the genetic heterogeneity in substrains of
SHR and SHRSP, several approaches are currently in
progress. In order to establish a system to facilitate the
systematic collection of rat strains and genetic
characterization, the National BioResource Project-Rat
(NBRP-Rat) was launched in 2002 [80]. By the end of
2008, more than 500 rat strains, including substrains of
SHR and SHRSP, had been deposited in the NBRP-Rat.
With this database, researchers can select a rat strain
(e.g., SHR/Izm) to instantly compare its genetic back-
ground against all rat strains typed at NBRP-Rat [81].
Such a phenotypic ‘Strain Ranking’ allows visual data
scoring, which provides an opportunity to easily and sim-
ultaneously compare phenotypic values for multiple rat
strains. This database could in theory be applied to find
genetic differences between the substrains with a different
phenotype. Needless to say, this approach will not imme-
diately resolve the major heterogeneity between strains,
but a huge rat repository is a reasonable attempt.
Another approach is the congenic strategy based on
the genome-wide linkage or quantitative trait loci (QTL)
analysis to examine the effects of polygenic trait on the
stroke phenotype. Jeffs et al. identified 3 major QTL on
chromosomes 1, 4, and 5 related to stroke sensitivity or
large infarct size in the SHRSP after MCAO by perform-
ing a genome scan in an F2 cross of SHRSPGla and
WKYGla [82]. Recently, a novel gene-targeting technol-
ogy utilizing zinc-finger nucleuses, which does not rely
on using species-specific embryonic stem cell lines, has
been proved to work successfully even in rats to gener-
ate a knockout of specific DNA regions [83]. However,
this method is not applicable to the search for new gen-
etic traits in SHR or SHRSP, because the genes or spe-
cific DNA regions for essential hypertension or stroke
have not been identified in either animals or human
beings. Almost all common diseases including stroke are
based on polygenes. Stroke falls within the category ofcomplex traits, arising from numerous gene-gene and
gene-environment interactions [84,85]. To overcome this
complexity, the role of identified QTL on stroke suscep-
tibility is currently studied through the production of
congenic lines: one or several QTL can be replaced with
those of the control strain to examine functional evi-
dence for the role of genes distinct between the two
strains. For example, a blood pressure QTL on rat
chromosome 1 was introgressed from WKY/Izm to
SHRSP/Izm by repeated backcrossing to cancel out the
heterogeneity in genetic background between the strains.
This congenic removal of the blood pressure QTL
increased collateral CBF after MCAO, and despite a small
decrease in blood pressure, demonstrated a substantial re-
duction in infarct volume after MCAO compared with
SHRSP/Izm, showing a beneficial effect beyond blood
pressure [66]. Congenic substrains are used to narrow
down the implicated congenic segment to aid the identifi-
cation of positional candidate genes [86]. As Aitman et al.
showed, microarray combined with congenic strategy
may lead to the identification of a causative gene once
congenic strains containing smaller QTL have been pro-
duced [87]. The congenic strategy would be particularly
useful to investigate the substrain differences in SHR and
SHRSP or stroke proneness in the future.
Concluding comments
We have reviewed the early development of various focal
ischemia models in substrains of SHR, and summarized
recent reports on this topic. Although SHR, which have
comorbidity (i.e., spontaneous hypertension), are suitable
for stroke research, only 11% of animal experiments on
neuroprotection involved testing in hypertensive rats
[30]. Distal MCAO without carotid occlusions in SHR is
best suited for the penumbra concept. To translate the
results in animal models into human stroke, common
mechanisms underlying the ischemic injury or protec-
tion by therapy need to be elucidated both in the animal
model and human stroke. One of the confounding fac-
tors is that genetic heterogeneity among substrains of
SHR and SHRSP may make the situation complicated.
Therefore, we attempted to provide an overview of focal
ischemia models in diverse substrains of SHR. Spin-off
findings from recent studies were that age, body weight,
and even blood pressure of SHR were not indicated in a
number of articles. We would like to emphasize the im-
portance of these basic physiological parameters in light
of the different phenotypes among substrains of SHR.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
HY conducted the literature search and wrote manuscript. TN is responsible
for critically revising for intellectual content. Both authors read and approved
the final manuscript.
Yao and Nabika Journal of Translational Medicine 2012, 10:139 Page 15 of 17
http://www.translational-medicine.com/content/10/1/139Acknowledgements
We thank Toshiyuki Sasaguri, M.D. for helpful discussion, and Katherine
Kawaharada for editing the manuscript.
Author details
1Laboratory for Neurochemistry, Center for Emotional and Behavioral
Disorders, National Hospital Organization Hizen Psychiatric Center, Mitsu 160,
Yoshinogari, Kanzaki, Saga, 842–0192, Japan. 2Department of Functional
Pathology, Shimane University School of Medicine, Izumo, Japan.
Received: 15 March 2012 Accepted: 2 July 2012
Published: 6 July 2012
References
1. Okamoto K, Aoki K: Development of a strain of spontaneously
hypertensive rats. Jpn Circ J 1963, 27:282–293.
2. Okamoto K, Yamori Y, Nagaoka A: Establishment of the stroke-prone
spontaneously hypertensive rat. Circ Res 1974, 34/35:I143–I153.
3. Jacewicz M, Tanabe J, Pulsinelli WA: The CBF threshold and dynamics for
focal cerebral infarction in spontaneously hypertensive rats. J Cereb Blood
Flow Metab 1992, 12:359–370.
4. Kaplan B, Brint S, Tanabe J, Jacewicz M, Wang XJ, Pulsinelli W: Temporal
thresholds for neocortical infarction in rats subjected to reversible focal
cerebral ischemia. Stroke 1991, 22:1032–1039.
5. Nabika T, Nara Y, Ikeda K, Endo J, Yamori Y: Genetic heterogeneity of the
spontaneously hypertensive rat. Hypertension 1991, 18:12–16.
6. St Lezin E, Simonet L, Pravenec M, Kurtz TW: Hypertensive strains and
normotensive 'control' strains. How closely are they related? Hypertension
1992, 19:419–424.
7. Johnson ML, Ely DL, Turner ME: Genetic divergence between the
Wistar-Kyoto rat and the spontaneously hypertensive rat. Hypertension
1992, 19:425–427.
8. Yamori Y, Horie R, Handa H, Sato M, Fukase M: Pathogenetic similarity of
strokes in stroke-prone spontaneously hypertensive rats and humans.
Stroke 1976, 7:46–53.
9. Bailey EL, Smith C, Sudlow CL, Wardlaw JM: Is the spontaneously
hypertensive stroke prone rat a pertinent model of sub cortical ischemic
stroke? A systematic review. Int J Stroke. 2011, 6:434–444.
10. Hainsworth AH, Markus HS: Do in vivo experimental models reflect
human cerebral small vessel disease? A systematic review. J Cereb Blood
Flow Metab 2008, 28:1877–1891.
11. Nabika T, Cui Z, Masuda J: The stroke-prone spontaneously hypertensive
rat: how good is it as a model for cerebrovascular diseases? Cell Mol
Neurobiol 2004, 24:639–646.
12. Rubattu S, Hubner N, Ganten U, Evangelista A, Stanzione R, Di Angelantonio
E, Plehm R, Langanki R, Gianazza E, Sironi L, D'Amati G, Volpe M: Reciprocal
congenic lines for a major stroke QTL on rat chromosome 1. Physiol
Genomics 2006, 27:108–113.
13. Tamura A, Graham DI, McCulloch J, Teasdale GM: Focal cerebral ischaemia
in the rat: 1. Description of technique and early neuropathological
consequences following middle cerebral artery occlusion. J Cereb Blood
Flow Metab 1981, 1:53–60.
14. Coyle P, Jokelainen PT: Differential outcome to middle cerebral artery
occlusion in spontaneously hypertensive stroke-prone rats (SHRSP) and
Wistar Kyoto (WKY) rats. Stroke 1983, 14:605–611.
15. Duverger D, MacKenzie ET: The quantification of cerebral infarction following
focal ischemia in the rat: influence of strain, arterial pressure, blood glucose
concentration, and age. J Cereb Blood Flow Metab 1988, 8:449–461.
16. Brint S, Jacewicz M, Kiessling M, Tanabe J, Pulsinelli W: Focal brain ischemia
in the rat: methods for reproducible neocortical infarction using tandem
occlusion of the distal middle cerebral and ipsilateral common carotid
arteries. J Cereb Blood Flow Metab 1988, 8:474–485.
17. Yao H, Sugimori H, Fukuda K, Takada J, Ooboshi H, Kitazono T, Ibayashi S,
Iida M: Photothrombotic middle cerebral artery occlusion and
reperfusion laser system in spontaneously hypertensive rats. Stroke 2003,
34:2716–2721.
18. Astrup J, Siesjö BK, Symon L: Thresholds in cerebral ischemia - the
ischemic penumbra. Stroke 1981, 12:723–725.
19. Furspan PB, Rinaldi GJ, Hoffman K, Bohr DF: Dietary calcium and cell
membrane abnormality in genetic hypertension. Hypertension 1989,
13:727–730.20. Fujii K, Weno BL, Baumbach GL, Heistad DD: Effect of antihypertensive
treatment on focal cerebral infarction. Hypertension 1992, 19:713–716.
21. Watson BD, Dietrich WD, Busto R, Wachtel MS, Ginsberg MD: Induction of
reproducible brain infarction by photochemically initiated thrombosis.
Ann Neurol 1985, 17:497–504.
22. Prado R, Watson BD, Zhao W, Yao H, Busto R, Dietrich WD, Ginsberg MD:
L-arginine does not improve cortical perfusion or histopathological
outcome in spontaneously hypertensive rats subjected to distal middle
cerebral artery photothrombotic occlusion. J Cereb Blood Flow Metab
1996, 16:612–22.
23. Yao H, Ibayashi S, Sugimori H, Fujii K, Fujishima M: Simplified model of
krypton laser-induced thrombotic distal middle cerebral artery occlusion
in spontaneously hypertensive rats. Stroke 1996, 27:333–336.
24. Cai H, Yao H, Ibayashi S, Uchimura H, Fujishima M: Photothrombotic
middle cerebral artery occlusion in spontaneously hypertensive rats:
influence of substrain, gender, and distal middle cerebral artery patterns
on infarct size. Stroke 1998, 29:1982–1986.
25. Ogata J, Fujishima M, Morotomi Y, Omae T: Cerebral infarction following
bilateral carotid artery ligation in normotensive and spontaneously
hypertensive rats: a pathological study. Stroke 1976, 7:54–60.
26. Watson BD, Prado R, Veloso A, Brunschwig JP, Dietrich WD: Cerebral blood
flow restoration and reperfusion injury after ultraviolet laser-facilitated
middle cerebral artery recanalization in rat thrombotic stroke. Stroke
2002, 33:428–434.
27. Yao H, Nabika T: Characterizing photothrombotic distal middle cerebral
artery occlusion and YAG laser-induced reperfusion model in the Izumo
strain of spontaneously hypertensive rats. Cell Mol Neurobiol 2011, 31:57–63.
28. Koizumi J, Yoshida Y, Nakazawa T, Ooneda G: Experimental studies of
ischemic brain edema. I: a new experimental model of cerebral
embolism in rats in which recirculation can be introdued in the ischemic
area. Jpn J Stroke 1986, 8:1–8.
29. Longa EZ, Weinstein PR, Carlson S, Cummins R: Reversible middle cerebral
artery occlusion without craniectomy in rats. Stroke 1989, 20:84–91.
30. Howells DW, Porritt MJ, Rewell SS, O'Collins V, Sena ES, van der Worp HB,
Traystman RJ, Macleod MR: Different strokes for different folks: the rich
diversity of animal models of focal cerebral ischemia. J Cereb Blood Flow
Metab 2010, 30:1412–1431.
31. Kawamura S, Li Y, Shirasawa M, Yasui N, Fukasawa H: Protective effect of
nilvadipine on focal cerebral ischemia in spontaneously hypertensive
rats. Neurol Med Chir (Tokyo) 1996, 36:151–155.
32. Alkayed NJ, Harukuni I, Kimes AS, London ED, Traystman RJ, Hurn PD:
Gender-linked brain injury in experimental stroke. Stroke 1998,
29:159–165.
33. Lakhan SE, Kirchgessner A, Hofer M: Inflammatory mechanisms in ischemic
stroke: therapeutic approaches. J Transl Med 2009, 7:7–97.
34. Kanemitsu H, Nakagomi T, Tamura A, Tsuchiya T, Kono G, Sano K:
Differences in the extent of primary ischemic damage between middle
cerebral artery coagulation and intraluminal occlusion models. J Cereb
Blood Flow Metab 2002, 22:1196–1204.
35. Henning EC, Latour LL, Hallenbeck JM, Warach S: Reperfusion-associated
hemorrhagic transformation in SHR rats: evidence of symptomatic
parenchymal hematoma. Stroke 2008, 39:3405–3410.
36. Guan W, Kozak A, Fagan SC: Drug repurposing for vascular protection
after acute ischemic stroke. Acta Neurochir Suppl 2011, 111:295–298.
37. Yamashita T, Kamiya T, Deguchi K, Inaba T, Zhang H, Shang J, Miyazaki K,
Ohtsuka A, Katayama Y, Abe K: Dissociation and protection of the
neurovascular unit after thrombolysis and reperfusion in ischemic rat
brain. J Cereb Blood Flow Metab 2009, 29:715–725.
38. The National Institute of Neurological Disorders and Stroke rt-PA Stroke
Study Group: Tissue plasminogen activator for acute ischemic stroke.
N Engl J Med 1995, 333:1581–1587.
39. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V,
Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N,
Toni D: ECASS Investigators: Thrombolysis with alteplase 3 to 4.5 hours
after acute ischemic stroke. N Engl J Med 2008, 359:1317–1329.
40. Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Dávalos A, Erilä T,
Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Köhrmann M, Larrue V,
Lees KR, Machnig T, Roine RO, Toni D, Vanhooren G: Safe Implementation
of Thrombolysis in Stroke-MOnitoring STudy Investigators: Multivariable
analysis of outcome predictors and adjustment of main outcome results
to baseline data profile in randomized controlled trials: Safe
Yao and Nabika Journal of Translational Medicine 2012, 10:139 Page 16 of 17
http://www.translational-medicine.com/content/10/1/139Implementation of Thrombolysis in Stroke-MOnitoring STudy
(SITS-MOST). Stroke 2008, 39:3316–3322.
41. Asahi M, Asahi K, Wang X, Lo EH: Reduction of tissue plasminogen
activator-induced hemorrhage and brain injury by free radical spin
trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow
Metab 2000, 20:452–457.
42. Tejima E, Katayama Y, Suzuki Y, Kano T, Lo EH: Hemorrhagic transformation
after fibrinolysis with tissue plasminogen activator: evaluation of role of
hypertension with rat thromboembolic stroke model. Stroke 2001,
32:1336–1340.
43. Sun L, Zhou W, Mueller C, Sommer C, Heiland S, Bauer AT, Marti HH,
Veltkamp R: Oxygen therapy reduces secondary hemorrhage after
thrombolysis in thromboembolic cerebral ischemia. J Cereb Blood Flow
Metab 2010, 30:1651–1660.
44. Fujiwara N, Murata Y, Arai K, Egi Y, Lu J, Wu O, Singhal AB, Lo EH:
Combination therapy with normobaric oxygen (NBO) plus thrombolysis
in experimental ischemic stroke. BMC Neurosci 2009, 10:79.
45. Astrup J, Symon L, Branston NM, Lassen NA: Cortical evoked potential and
extracellular K+ and H+ at critical levels of brain ischemia. Stroke 1977,
8:51–57.
46. Zhao W, Belayev L, Ginsberg MD: Transient middle cerebral artery
occlusion by intraluminal suture: II. Neurological deficits, and pixel-based
correlation of histopathology with local blood flow and glucose
utilization. J Cereb Blood Flow Metab 1997, 17:1281–1290.
47. Hossmann KA: Viability thresholds and the penumbra of focal ischemia.
Ann Neurol 1994, 36:557–565.
48. Sun PZ, Zhou J, Sun W, Huang J, van Zijl PC: Detection of the ischemic
penumbra using pH-weighted MRI. J Cereb Blood Flow Metab 2007,
27:1129–1136.
49. Heiss WD: The ischemic penumbra: correlates in imaging and
implications for treatment of ischemic stroke. The Johann Jacob Wepfer
award 2011. Cerebrovasc Dis 2011, 32:307–320.
50. Campbell BC, Purushotham A, Christensen S, Desmond PM, Nagakane Y,
Parsons MW, Lansberg MG, Mlynash M, Straka M, De Silva DA, Olivot JM,
Bammer R, Albers GW, Donnan GA, Davis SM: The infarct core is well
represented by the acute diffusion lesion: sustained reversal is
infrequent. J Cereb Blood Flow Metab 2012, 32:50–56.
51. Jones SC, Kharlamov A, Yanovski B, Kim DK, Easley KA, Yushmanov VE,
Ziolko SK, Boada FE: Stroke onset time using sodium MRI in rat focal
cerebral ischemia. Stroke 2006, 37:883–888.
52. De Silva DA, Brekenfeld C, Ebinger M, Christensen S, Barber PA, Butcher KS,
Levi CR, Parsons MW, Bladin CF, Donnan GA, Davis SM: Echoplanar Imaging
Thrombolytic Evaluation Trial (EPITHET) Investigators: The benefits of
intravenous thrombolysis relate to the site of baseline arterial occlusion
in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET).
Stroke 2010, 41:295–299.
53. Letourneur A, Roussel S, Toutain J, Bernaudin M, Touzani O: Impact
of genetic and renovascular chronic arterial hypertension on the
acute spatiotemporal evolution of the ischemic penumbra: a
sequential study with MRI in the rat. J Cereb Blood Flow Metab
2011, 31:504–513.
54. Yao H, Okada Y, Ibayashi S: Therapeutic time window for YAG
laser-induced reperfusion of thrombotic stroke in hypertensive rats.
Neuroreport 2002, 13:1005–1008.
55. Liszczak TM, Hedley-Whyte ET, Adams JF, Han DH, Kolluri VS, Vacanti FX,
Heros RC, Zervas NT: Limitations of tetrazolium salts in delineating
infarcted brain. Acta Neuropathol 1984, 65:150–157.
56. Zille M, Farr TD, Przesdzing I, Müller J, Sommer C, Dirnagl U, Wunder A:
Visualizing cell death in experimental focal cerebral ischemia:
promises, problems, and perspectives. J Cereb Blood Flow Metab. 2012,
32:213–231.
57. Yao H, Yoshii N, Akira T, Nakahara T: Reperfusion-induced temporary
appearance of therapeutic window in penumbra after 2 h of
photothrombotic middle cerebral artery occlusion in rats. J Cereb Blood
Flow Metab 2009, 29:565–574.
58. Yao H, Takasawa R, Fukuda K, Shiokawa D, Sadanaga-Akiyoshi F, Ibayashi S,
Tanuma S, Uchimura H: DNA fragmentation in ischemic core and
penumbra in focal cerebral ischemia in rats. Brain Res Mol Brain Res 2001,
91:112–118.
59. Yao H, Nakahara T, Nakagawa N, Hashimoto K, Kuroki T: Regional and
temporal changes in proteomic profile after middle cerebral arteryocclusion with or without reperfusion in rats. Neurochem Res 2009,
34:1999–2007.
60. Braeuninger S, Kleinschnitz C: Rodent models of focal cerebral ischemia:
procedural pitfalls and translational problems. Exp Transl Stroke Med 2009,
25:1–8.
61. Dirnagl U, Pulsinelli W: Autoregulation of cerebral blood flow in
experimental focal brain ischemia. J Cereb Blood Flow Metab 1990,
10:327–336.
62. Zhu CZ, Auer RN: Graded hypotension and MCA occlusion duration: effect
in transient focal ischemia. J Cereb Blood Flow Metab 1995, 15:980–988.
63. Zausinger S, Baethmann A, Schmid-Elsaesser R: Anesthetic methods in rats
determine outcome after experimental focal cerebral ischemia:
mechanical ventilation is required to obtain controlled experimental
conditions. Brain Res Brain Res Protoc 2002, 9:112–121.
64. Yao H, Matsumoto T, Hirano M, Kuroki T, Tsutsumi T, Uchimura H,
Nakamura K, Nakahara T, Fujishima M: Involvement of brain stem
noradrenergic neurons in the development of hypertension in
spontaneously hypertensive rats. Neurochem Res 1989, 14:75–79.
65. Mori S, Kato M, Fujishima M: Impaired maze learning and cerebral glucose
utilization in aged hypertensive rats. Hypertension 1995, 25:545–553.
66. Yao H, Cui ZH, Masuda J, Nabika T: Congenic removal of a QTL for blood
pressure attenuates infarct size produced by middle cerebral artery
occlusion in hypertensive rats. Physiol Genomics 2007, 30:69–73.
67. DeBow SB, Clark DL, MacLellan CL, Colbourne F: Incomplete assessment of
experimental cytoprotectants in rodent ischemia studies. Can J Neurol
Sci. 2003, 30:368–374.
68. Hurn PD, Vannucci SJ, Hagberg H: Adult or perinatal brain injury: does sex
matter? Stroke 2005, 36:193–195.
69. Fukuda K, Yao H, Ibayashi S, Nakahara T, Uchimura H, Fujishima M:
Ovariectomy exacerbates and estrogen replacement attenuates
photothrombotic focal ischemic brain injury in rats. Stroke 2000,
31:155–160.
70. Macleod MR, O'Collins T, Howells DW, Donnan GA: Pooling of animal
experimental data reveals influence of study design and publication
bias. Stroke 2004, 35:1203–1208.
71. Stroke Therapy Academic Industry Roundtable (STAIR): Recommendations
for Standards Regarding Preclinical Neuroprotective and Restorative
Drug Development. Stroke 1999, 30:2752–2758.
72. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA: Systematic
review and metaanalysis of the efficacy of FK506 in experimental stroke.
J Cereb Blood Flow Metab 2005, 25:713–721.
73. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells
DW: 1,026 experimental treatments in acute stroke. Ann Neurol 2006,
59:467–477.
74. Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD,
Richter PS, Roine RO, Terént A, Thijs V: Berge E; SCAST Study Group: The
angiotensin-receptor blocker candesartan for treatment of acute stroke
(SCAST): a randomised, placebo-controlled, double-blind trial. Lancet
2011, 377:741–750.
75. Kozak W, Kozak A, Johnson MH, Elewa HF, Fagan SC: Vascular protection
with candesartan after experimental acute stroke in hypertensive rats: a
dose–response study. J Pharmacol Exp Ther 2008, 326:773–782.
76. McCabe C, Gallagher L, Gsell W, Graham D, Dominiczak AF, Macrae IM:
Differences in the evolution of the ischemic penumbra in stroke-prone
spontaneously hypertensive and Wistar-Kyoto rats. Stroke. 2009,
40:3864–3868.
77. Dijkhuizen RM, Asahi M, Wu O, Rosen BR, Lo EH: Rapid breakdown of
microvascular barriers and subsequent hemorrhagic transformation after
delayed recombinant tissue plasminogen activator treatment in a rat
embolic stroke model. Stroke. 2002, 33:2100–2104.
78. Riyamongkol P, Zhao W, Liu Y, Belayev L, Busto R, Ginsberg MD: Automated
registration of laser Doppler perfusion images by an adaptive correlation
approach: application to focal cerebral ischemia in the rat. J Neurosci
Methods 2002, 122:79–90.
79. Ren Y, Hashimoto M, Pulsinelli WA, Nowak TS Jr: Hypothermic protection
in rat focal ischemia models: strain differences and relevance to
"reperfusion injury". J Cereb Blood Flow Metab 2004, 24:42–53.
80. Serikawa T, Mashimo T, Takizawa A, Okajima R, Maedomari N, Kumafuji K,
Tagami F, Neoda Y, Otsuki M, Nakanishi S, Yamasaki K, Voigt B, Kuramoto T:
National BioResource Project-Rat and related activities. Exp Anim 2009,
58:333–341.
Yao and Nabika Journal of Translational Medicine 2012, 10:139 Page 17 of 17
http://www.translational-medicine.com/content/10/1/13981. Mashimo T, Voigt B, Tsurumi T, Naoi K, Nakanishi S, Yamasaki K, Kuramoto T,
Serikawa T: A set of highly informative rat simple sequence length
polymorphism (SSLP) markers and genetically defined rat strains. BMC
Genet 2006, 7:19.
82. Jeffs B, Clark JS, Anderson NH, Gratton J, Brosnan MJ, Gauguier D, Reid JL,
Macrae IM, Dominiczak AF: Sensitivity to cerebral ischaemic insult in a rat
model of stroke is determined by a single genetic locus. Nat Genet 1997,
16:364–367.
83. Mashimo T, Takizawa A, Voigt B, Yoshimi K, Hiai H, Kuramoto T, Serikawa T:
Generation of knockout rats with X-linked severe combined
immunodeficiency (X-SCID) using zinc-finger nucleases. PLoS One 2010,
5:e8870.
84. Rubattu S, Gigante B, Stanzione R, De Paolis P, Tarasi D, Volpe M: In the
search for stroke genes: a long and winding road. Am J Hypertens 2004,
17:197–202.
85. Carr FJ, McBride MW, Carswell HV, Graham D, Strahorn P, Clark JS,
Charchar FJ, Dominiczak AF: Genetic aspects of stroke: human and
experimental studies. J Cereb Blood Flow Metab 2002, 22:767–773.
86. Graham D, McBride MW, Gaasenbeek M, Gilday K, Beattie E, Miller WH,
McClure JD, Polke JM, Montezano A, Touyz RM, Dominiczak AF: Candidate
genes that determine response to salt in the stroke-prone
spontaneously hypertensive rat: congenic analysis. Hypertension 2007,
50:1134–1141.
87. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN,
Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E,
Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J:
Identification of Cd36 (Fat) as an insulin-resistance gene causing
defective fatty acid and glucose metabolism in hypertensive rats. Nat
Genet 1999, 21:76–83.
doi:10.1186/1479-5876-10-139
Cite this article as: Yao and Nabika: Standards and pitfalls of focal
ischemia models in spontaneously hypertensive rats: With a systematic
review of recent articles. Journal of Translational Medicine 2012 10:139.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
